Apoptosis imaging to monitor cancer therapy: The road to fast treatment evaluation?

Current Pharmaceutical Biotechnology

Volumn 13, Issue 4, 2012, Pages 571-583

  de Saint Hubert, Marijke D ^a,d   Bauwens, Matthias ^b,d   Verbruggen, Alfons ^b   Mottaghy, Felix M ^a,c,d  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^d MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

18F ML10; AnnexinA5; Apoptosis; Molecular imaging of therapy response

Indexed keywords

5 FLUOROPENTYL 2 METHYLMALONIC ACID; CYTOCHROME C; FAS LIGAND; FLUORINE 18; GALLIUM 68; INITIATOR CASPASE; IODINE 123; ISATIN; LANCOVUTIDE; LIPOCORTIN 5; LUTETIUM 177; METHYLMALONIC ACID; MITOCHONDRIAL PROTEIN; PERTECHNETIC ACID TC 99M; PHOSPHATIDYLETHANOLAMINE; PHOSPHATIDYLSERINE; TECHNETIUM 99M; UNCLASSIFIED DRUG; YTTRIUM 90;

APOPTOSIS; ARTICLE; BINDING AFFINITY; BINDING SITE; BRAIN TUMOR; CANCER THERAPY; CELL DEATH; CELL MEMBRANE DEPOLARIZATION; DRUG HALF LIFE; DRUG UPTAKE; FOLLOW UP; HUMAN; IN VIVO STUDY; ISOTOPE LABELING; KIDNEY CLEARANCE; LIPOPHILICITY; LUNG CANCER; LYMPHOMA; MOLECULAR IMAGING; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT RESPONSE; URINARY EXCRETION;

ANIMALS; APOPTOSIS; HUMANS; MOLECULAR IMAGING; NECROSIS; NEOPLASMS; RADIOPHARMACEUTICALS;

EID: 84857747068     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920112799436320     Document Type: Article

References (71)

1. Eisenhauer, E.A.; Therasse, P.; Bogaerts, J.; Schwartz, L.H.; Sargent, D.; Ford, R.; Dancey, J.; Arbuck, S.; Gwyther, S.; Mooney, M.; Rubinstein, L.; Shankar, L.; Dodd, L.; Kaplan, R.; Lacombe, D.; Verweij, J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer, 2009, 45(2), 228-247.
2. Spaepen, K.; Stroobants, S.; Dupont, P.; Vandenberghe, P.; Thomas, J.; De Groot, T.; Balzarini, J.; De Wolf-Peeters, C.; Mortelmans, L.; Verhoef, G. Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann. Oncol., 2002, 13(9), 1356-1363.
3. Spaepen, K.; Stroobants, S.; Dupont, P.; Van Steenweghen, S.; Thomas, J.; Vandenberghe, P.; Vanuytsel, L.; Bormans, G.; Balzarini, J.; De Wolf-Peeters, C.; Mortelmans, L.; Verhoef, G. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods? J. Clin. Oncol., 2001, 19(2), 414-419.
4. Pottgen, C.; Levegrun, S.; Theegarten, D.; Marnitz, S.; Grehl, S.; Pink, R.; Eberhardt, W.; Stamatis, G.; Gauler, T.; Antoch, G.; Bockisch, A.; Stuschke, M. Value of 18F-fluoro-2-deoxy-Dglucose- positron emission tomography/computed tomography in non-small-cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy. Clin. Cancer Res., 2006, 12(1), 97-106.
5. Brepoels, L.; Stroobants, S.; Vandenberghe, P.; Spaepen, K.; Dupont, P.; Nuyts, J.; Bormans, G.; Mortelmans, L.; Verhoef, G.; De Wolf-Peeters, C. Effect of corticosteroids on 18F-FDG uptake in tumor lesions after chemotherapy. J. Nucl. Med., 2007, 48(3), 390-397.
6. Spaepen, K.; Stroobants, S.; Dupont, P.; Bormans, G.; Balzarini, J.; Verhoef, G.; Mortelmans, L.; Vandenberghe, P.; De Wolf-Peeters, C. [(18)F]FDG PET monitoring of tumour response to chemotherapy: does [(18)F]FDG uptake correlate with the viable tumour cell fraction? Eur. J. Nucl. Med. Mol. Imaging, 2003, 30(5), 682-688.
7. Seitz, U.; Wagner, M.; Neumaier, B.; Wawra, E.; Glatting, G.; Leder, G.; Schmid, R.M.; Reske, S.N. Evaluation of pyrimidine metabolising enzymes and in vitro uptake of 3'-[(18)F]fluoro-3'- deoxythymidine ([(18)F]FLT) in pancreatic cancer cell lines. Eur. J. Nucl. Med. Mol. Imaging, 2002, 29(9), 1174-1181.
8. Leyton, J.; Latigo, J.R.; Perumal, M.; Dhaliwal, H.; He, Q.; Aboagye, E. O. Early detection of tumor response to chemotherapy by 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography: the effect of cisplatin on a fibrosarcoma tumor model in vivo. Cancer Res., 2005, 65(10), 4202-4210.
9. Been, L.B.; Suurmeijer, A.J.; Cobben, D.C.; Jager, P.L.; Hoekstra, H.J.; Elsinga, P.H. [18F]FLT-PET in oncology: current status and opportunities. Eur. J. Nucl. Med. Mol. Imaging, 2004, 31(12), 1659-1672.
10. Weber, W.A. Monitoring tumor response to therapy with 18F-FLT PET. J. Nucl. Med., 2010, 51(6), 841-844.
11. De Saint-Hubert, M.; Prinsen, K.; Mortelmans, L.; Verbruggen, A.; Mottaghy, F. M. Molecular imaging of cell death. Methods, 2009, 48(2), 178-187.
12. Eguchi, Y.; Shimizu, S.; Tsujimoto, Y. Intracellular ATP levels determine cell death fate by apoptosis or necrosis. Cancer Res., 1997, 57(10), 1835-1840.
13. Perek, N.; Sabido, O.; Le Jeune, N.; Prevot, N.; Vergnon, J.M.; Clotagatide, A.; Dubois, F. Could 99mTc-glucarate be used to evaluate tumour necrosis? In vitro and in vivo studies in leukaemic tumour cell line U937. Eur. J. Nucl. Med. Mol. Imaging, 2008, 35(7), 1290-1298.
14. Wang, H.; Li, J.; Chen, F.; De Keyzer, F.; Yu, J.; Feng, Y.; Nuyts, J.; Marchal, G.; Ni, Y. Morphological, functional and metabolic imaging biomarkers: assessment of vascular-disrupting effect on rodent liver tumours. Eur. Radiol., 2010, 20(8), 2013-2026.
15. Ogasawara, J.; Watanabe-Fukunaga, R.; Adachi, M.; Matsuzawa, A.; Kasugai, T.; Kitamura, Y.; Itoh, N.; Suda, T.; Nagata, S. Lethal effect of the anti-Fas antibody in mice. Nature, 1993, 364(6440), 806-809.
16. Hanahan, D.; Weinberg, R.A. The hallmarks of cancer. Cell, 2000, 100(1), 57-70.
17. Fadok, V.A.; Voelker, D.R.; Campbell, P.A.; Cohen, J.J.; Bratton, D.L.; Henson, P.M. Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J. Immunol., 1992, 148(7), 2207-2216.
18. Emoto, K.; Toyama-Sorimachi, N.; Karasuyama, H.; Inoue, K.; Umeda, M. Exposure of phosphatidylethanolamine on the surface of apoptotic cells. Exp. Cell Res., 1997, 232(2), 430-434.
19. Taylor, R.C.; Cullen, S.P.; Martin, S.J. Apoptosis: controlled demolition at the cellular level. Nat. Rev. Mol. Cell Biol., 2008, 9(3), 231-241.
20. Martin, S.J.; Reutelingsperger, C.P.; McGahon, A.J.; Rader, J.A.; van Schie, R.C.; LaFace, D.M.; Green, D.R. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. J. Exp. Med., 1995, 182(5), 1545-1556.
21. Koopman, G.; Reutelingsperger, C.P.; Kuijten, G.A.; Keehnen, R.M.; Pals, S.T.; van Oers, M.H. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood, 1994, 84(5), 1415-1420.
22. Marki, F.; Hanni, E.; Fredenhagen, A.; van, O. J. Mode of action of the lanthionine-containing peptide antibiotics duramycin, duramycin B and C, and cinnamycin as indirect inhibitors of phospholipase A2. Biochem. Pharmacol., 1991, 42(10), 2027-2035.
23. Grimberg, H.; Levin, G.; Shirvan, A.; Cohen, A.; Yogev-Falach, M.; Reshef, A.; Ziv, I. Monitoring of tumor response to chemotherapy in vivo by a novel small-molecule detector of apoptosis. Apoptosis, 2009, 14(3), 257-267.
24. Reshef, A.; Shirvan, A.; Waterhouse, R. N.; Grimberg, H.; Levin, G.; Cohen, A.; Ulysse, L. G.; Friedman, G.; Antoni, G.; Ziv, I. Molecular imaging of neurovascular cell death in experimental cerebral stroke by PET. J. Nucl. Med., 2008, 49(9), 1520-1528.
25. Pan, M.H.; Gao, D.W.; Feng, J.; He, J.; Seo, Y.; Tedesco, J.; Wolodzko, J.G.; Hasegawa, B.H.; Franc, B.L. Biodistributions of 177Lu- and 111In-labeled 7E11 antibodies to prostate-specific membrane antigen in xenograft model of prostate cancer and potential use of 111In-7E11 as a pre-therapeutic agent for 177Lu- 7E11 radioimmunotherapy. Mol. Imaging Biol., 2009, 11(3), 159-166.
26. Tait, J.F.; Smith, C.; Levashova, Z.; Patel, B.; Blankenberg, F.G.; Vanderheyden, J. L. Improved detection of cell death in vivo with annexin V radiolabeled by site-specific methods. J. Nucl. Med., 2006, 47(9), 1546-1553.
27. Tait, J.F.; Brown, D.S.; Gibson, D.F.; Blankenberg, F.G.; Strauss, H.W. Development and characterization of annexin V mutants with endogenous chelation sites for (99m)Tc. Bioconjug. Chem., 2000, 11(6), 918-925.
28. Blankenberg, F.G.; Katsikis, P.D.; Tait, J.F.; Davis, R.E.; Naumovski, L.; Ohtsuki, K.; Kopiwoda, S.; Abrams, M.J.; Darkes, M.; Robbins, R.C.; Maecker, H.T.; Strauss, H.W. In vivo detection and imaging of phosphatidylserine expression during programmed cell death. Proc. Natl. Acad. Sci. USA, 1998, 95(11), 6349-6354.
29. Blankenberg, F.G.; Katsikis, P.D.; Tait, J.F.; Davis, R.E.; Naumovski, L.; Ohtsuki, K.; Kopiwoda, S.; Abrams, M.J.; Strauss, H.W. Imaging of apoptosis (programmed cell death) with 99mTc annexin V. J. Nucl. Med., 1999, 40(1), 184-191.
30. Zhao, M.; Zhu, X.; Ji, S.; Zhou, J.; Ozker, K.S.; Fang, W.; Molthen, R.C.; Hellman, R.S. 99mTc-labeled C2A domain of synaptotagmin I as a target-specific molecular probe for noninvasive imaging of acute myocardial infarction. J. Nucl. Med., 2006, 47(8), 1367-1374.
31. Lahorte, C.; Slegers, G.; Philippe, J.; Van de Wiele, C.; Dierckx, R.A. Synthesis and in vitro evaluation of 123I-labelled human recombinant annexin V. Biomol. Eng., 2001, 17(2), 51-53.
32. Grierson, J.R.; Yagle, K.J.; Eary, J.F.; Tait, J.F.; Gibson, D.F.; Lewellen, B.; Link, J.M.; Krohn, K.A. Production of [F- 18]fluoroannexin for imaging apoptosis with PET. Bioconjug. Chem., 2004, 15(2), 373-379.
33. Dekker, B.; Keen, H.; Shaw, D.; Disley, L.; Hastings, D.; Hadfield, J.; Reader, A.; Allan, D.; Julyan, P.; Watson, A.; Zweit, J. Functional comparison of annexin V analogues labeled indirectly and directly with iodine-124. Nucl. Med. Biol., 2005, 32(4), 403-413.
34. Li, X.; Link, J. M.; Stekhova, S.; Yagle, K.J.; Smith, C.; Krohn, K. A.; Tait, J.F. Site-specific labeling of annexin V with F-18 for apoptosis imaging. Bioconjug. Chem., 2008, 19(8), 1684-1688.
35. Bauwens, M.; De Saint-Hubert, M.; Devos, E.; et al. Site-specific 68Ga-labelled Annexin A5 as a PET imaging agent for apoptosis. J. Nucl. Med. Bio., 2011, 38(3), 381-392.
36. De Saint-Hubert, M.; Mottaghy, F.M.; Vunckx, K.; Nuyts, J.; Fonge, H.; Prinsen, K.; Stroobants, S.; Mortelmans, L.; Deckers, N.; Hofstra, L.; Reutelingsperger, C. P.; Verbruggen, A.; Rattat, D. Site-specific labeling of 'second generation' annexin V with 99mTc(CO)3 for improved imaging of apoptosis in vivo. Bioorg. Med. Chem., 2010, 18(3), 1356-1363.
37. Tavare, R.; Torres Martin De, R.R.; Blower, P.J.; Mullen, G.E. Efficient site-specific radiolabeling of a modified C2A domain of synaptotagmin I with [99mTc(CO)3]+: a new radiopharmaceutical for imaging cell death. Bioconjug. Chem., 2009, 20(11), 2071-2081.
38. Tait, J.F.; Smith, C.; Blankenberg, F.G. Structural requirements for in vivo detection of cell death with 99mTc-annexin V. J. Nucl. Med., 2005, 46(5), 807-815.
39. Zhao, M.; Li, Z.; Bugenhagen, S. 99mTc-labeled duramycin as a novel phosphatidylethanolamine-binding molecular probe. J. Nucl. Med., 2008, 49(8), 1345-1352.
40. Zhou, D.; Chu, W.; Rothfuss, J.; Zeng, C.; Xu, J.; Jones, L.; Welch, M. J.; Mach, R. H. Synthesis, radiolabeling, and in vivo evaluation of an 18F-labeled isatin analog for imaging caspase-3 activation in apoptosis. Bioorg. Med. Chem. Lett., 2006, 16(19), 5041-5046.
41. Collingridge, D.R.; Glaser, M.; Osman, S.; Barthel, H.; Hutchinson, O.C.; Luthra, S.K.; Brady, F.; Bouchier-Hayes, L.; Martin, S.J.; Workman, P.; Price, P.; Aboagye, E.O. In vitro selectivity, in vivo biodistribution and tumour uptake of annexin V radiolabelled with a positron emitting radioisotope. Br. J. Cancer, 2003, 89(7), 1327-1333.
42. Yagle, K.J.; Eary, J.F.; Tait, J.F.; Grierson, J.R.; Link, J.M.; Lewellen, B.; Gibson, D.F.; Krohn, K.A. Evaluation of 18Fannexin V as a PET imaging agent in an animal model of apoptosis. J. Nucl. Med., 2005, 46(4), 658-666.
43. Sturgeon, S.A.; Towner, R.A. In vivo assessment of microcystin-LR-induced hepatotoxicity in the rat using proton nuclear magnetic resonance (1H-NMR) imaging. Biochim. Biophys. Acta, 1999, 1454(3), 227-235.
44. Fonge, H.; de Saint Hubert, M.; Vunckx, K.; Rattat, D.; Nuyts, J.; Bormans, G.; Ni, Y.; Reutelingsperger, C.; Verbruggen, A. Preliminary in vivo evaluation of a novel 99mTc-labeled HYNICcys-annexin A5 as an apoptosis imaging agent. Bioorg. Med. Chem. Lett., 2008, 18(13), 3794-3798.
45. Fonge, H.; Vunckx, K.; Wang, H.; Feng, Y.; Mortelmans, L.; Nuyts, J.; Bormans, G.; Verbruggen, A.; Ni, Y. Non-invasive detection and quantification of acute myocardial infarction in rabbits using mono-[123I]iodohypericin microSPECT. Eur. Heart J., 2008, 29(2), 260-269.
46. Watson, B.D.; Dietrich, W.D.; Busto, R.; Wachtel, M.S.; Ginsberg, M.D. Induction of reproducible brain infarction by photochemically initiated thrombosis. Ann. Neurol., 1985, 17(5), 497-504.
47. Bouet, V.; Freret, T.; Toutain, J.; Divoux, D.; Boulouard, M.; Schumann-Bard, P. Sensorimotor and cognitive deficits after transient middle cerebral artery occlusion in the mouse. Exp. Neurol., 2007, 203(2), 555-567.
48. Keen, H.G.; Dekker, B.A.; Disley, L.; Hastings, D.; Lyons, S.; Reader, A.J.; Ottewell, P.; Watson, A.; Zweit, J. Imaging apoptosis in vivo using 124I-annexin V and PET. Nucl. Med. Biol., 2005, 32(4), 395-402.
49. Murakami, Y.; Takamatsu, H.; Taki, J.; Tatsumi, M.; Noda, A.; Ichise, R.; Tait, J.F.; Nishimura, S. 18F-labelled annexin V: a PET tracer for apoptosis imaging. Eur. J. Nucl. Med. Mol. Imaging, 2004, 31(4), 469-474.
50. Luo, Q. Y.; Zhang, Z.Y.; Wang, F.; Lu, H.K.; Guo, Y.Z.; Zhu, R.S. Preparation, in vitro and in vivo evaluation of (99m)Tc-Annexin B1: a novel radioligand for apoptosis imaging. Biochem. Biophys. Res. Commun., 2005, 335(4), 1102-1106.
51. Faust, A.; Wagner, S.; Law, M. P.; Hermann, S.; Schnockel, U.; Keul, P.; Schober, O.; Schafers, M.; Levkau, B.; Kopka, K. The nonpeptidyl caspase binding radioligand (S)-1-(4-(2- [18F]Fluoroethoxy)-benzyl)-5-[1-(2-methoxymethylpyrrolidinyl)s ulfonyl]isatin ([18F]CbR) as potential positron emission tomography-compatible apoptosis imaging agent. Q. J. Nucl. Med. Mol. Imaging, 2007, 51(1), 67-73.
52. Cohen, A.; Shirvan, A.; Levin, G.; Grimberg, H.; Reshef, A.; Ziv, I. From the Gla domain to a novel small-molecule detector of apoptosis. Cell Res., 2009, 19(5), 625-637.
53. Lu, C.; Tanigawa, N. Spontaneous apoptosis is inversely related to intratumoral microvessel density in gastric carcinoma. Cancer Res., 1997, 57(2), 221-224.
54. Takei, T.; Kuge, Y.; Zhao, S.; Sato, M.; Strauss, H.W.; Blankenberg, F.G.; Tait, J.F.; Tamaki, N. Enhanced apoptotic reaction correlates with suppressed tumor glucose utilization after cytotoxic chemotherapy: use of 99mTc-Annexin V, 18F-FDG, and histologic evaluation. J. Nucl. Med., 2005, 46(5), 794-799.
55. Stephens, L.C.; Hunter, N.R.; Ang, K.K.; Milas, L.; Meyn, R.E. Development of apoptosis in irradiated murine tumors as a function of time and dose. Radiat. Res., 1993, 135(1), 75-80.
56. Takei, T.; Kuge, Y.; Zhao, S.; Sato, M.; Strauss, H.W.; Blankenberg, F.G.; Tait, J.F.; Tamaki, N. Time course of apoptotic tumor response after a single dose of chemotherapy: comparison with 99mTc-annexin V uptake and histologic findings in an experimental model. J. Nucl. Med., 2004, 45(12), 2083-2087.
57. Mandl, S.J.; Mari, C.; Edinger, M.; Negrin, R.S.; Tait, J.F.; Contag, C.H.; Blankenberg, F.G. Multi-modality imaging identifies key times for annexin V imaging as an early predictor of therapeutic outcome. Mol. Imaging, 2004, 3(1), 1-8.
58. Cornelissen, B.; Lahorte, C.; Kersemans, V.; Capriotti, G.; Bonanno, E.; Signore, A.; Van de, W.C.; Dierckx, R.A.; Slegers, G. In vivo apoptosis detection with radioiodinated Annexin V in LoVo tumour-bearing mice following Tipifarnib (Zarnestra, R115777) farnesyltransferase inhibitor therapy. Nucl. Med. Biol., 2005, 32(3), 233-239.
59. Wang, F.; Fang, W.; Zhao, M.; Wang, Z.; Ji, S.; Li, Y.; Zheng, Y. Imaging paclitaxel (chemotherapy)-induced tumor apoptosis with 99mTc C2A, a domain of synaptotagmin I: a preliminary study. Nucl. Med. Biol., 2008, 35(3), 359-364.
60. Nguyen, Q.D.; Smith, G.; Glaser, M.; Perumal, M.; Arstad, E.; Aboagye, E.O. Positron emission tomography imaging of druginduced tumor apoptosis with a caspase-3/7 specific [18F]-labeled isatin sulfonamide. Proc. Natl. Acad. Sci. USA, 2009, 106(38), 16375-16380.
61. Ashkenazi, A.; Herbst, R. S. To kill a tumor cell: the potential of proapoptotic receptor agonists. J. Clin. Invest., 2008, 118(6), 1979-1990.
62. Lahorte, C.M.; Van de Wiele, C.; Bacher, K.; van den Bossche, B.; Thierens, H.; Van, B.S.; Slegers, G.; Dierckx, R.A. Biodistribution and dosimetry study of 123I-rh-annexin V in mice and humans. Nucl. Med. Commun., 2003, 24(8), 871-880.
63. Kemerink, G.J.; Liu, X.; Kieffer, D.; Ceyssens, S.; Mortelmans, L.; Verbruggen, A.M.; Steinmetz, N.D.; Vanderheyden, J.L.; Green, A.M.; Verbeke, K. Safety, biodistribution, and dosimetry of 99mTc-HYNIC-annexin V, a novel human recombinant annexin V for human application. J. Nucl. Med., 2003, 44(6), 947-952.
64. Hofstra, L.; Dumont, E.A.; Thimister, P.W.; Heidendal, G.A.; DeBruine, A. P.; Elenbaas, T. W.; Boersma, H.H.; van Heerde, W.L.; Reutelingsperger, C. P. In vivo detection of apoptosis in an intracardiac tumor. JAMA, 2001, 285(14), 1841-1842.
65. Van de Wiele, C.; Lahorte, C.; Vermeersch, H.; Loose, D.; Mervillie, K.; Steinmetz, N.D.; Vanderheyden, J.L.; Cuvelier, C. A.; Slegers, G.; Dierck, R.A. Quantitative tumor apoptosis imaging using technetium-99m-HYNIC annexin V single photon emission computed tomography. J. Clin. Oncol., 2003, 21(18), 3483-3487.
66. Belhocine, T.; Steinmetz, N.; Hustinx, R.; Bartsch, P.; Jerusalem, G.; Seidel, L.; Rigo, P.; Green, A. Increased uptake of the apoptosis-imaging agent (99m)Tc recombinant human Annexin V in human tumors after one course of chemotherapy as a predictor of tumor response and patient prognosis. Clin. Cancer Res., 2002, 8(9), 2766-2774.
67. Haas, R.L.; de Jong, D.; Valdes Olmos, R.A.; Hoefnagel, C.A.; Van, I.; Heuvel, I.; Zerp, S. F.; Bartelink, H.; Verheij, M. In vivo imaging of radiation-induced apoptosis in follicular lymphoma patients. Int. J. Radiat. Oncol. Biol. Phys., 2004, 59(3), 782-787.
68. Kartachova, M.; van Zandwijk, N.; Burgers, S.; van Tinteren, H.; Verheij, M.; Valdes Olmos, R.A. Prognostic significance of 99mTc Hynic-rh-annexin V scintigraphy during platinum-based chemotherapy in advanced lung cancer. J. Clin. Oncol., 2007, 25(18), 2534-2539.
69. Verheij, M. Clinical biomarkers and imaging for radiotherapyinduced cell death. Cancer Metastasis. Rev., 2008, 27(3), 471-480.
70. Reshef, A.; Shirvan, A.; kselrod-Ballin, A.; Wall, A.; Ziv, I. Smallmolecule biomarkers for clinical PET imaging of apoptosis. J. Nucl. Med., 2010, 51(6), 837-840.
71. van Vulpen, M.; Kal, H.B.; Taphoorn, M.J.; El-Sharouni, S.Y. Changes in blood-brain barrier permeability induced by radiotherapy: implications for timing of chemotherapy? (Review). Oncol. Rep., 2002, 9(4), 683-688.